Switching From Liraglutide to a Weekly GLP-1: What the Labels Actually Say

If you have been taking daily liraglutide and you are moving to a once-weekly shot, you have probably gone looking for a conversion chart. Something that says 3 mg of Saxenda equals a particular dose of Wegovy, or that 1.8 mg of Victoza lines up with a particular dose of Ozempic.

That chart does not exist. Not because nobody has written one, but because no manufacturer has ever submitted one to the FDA and no label contains one. This article explains what the labels actually say, what the one relevant study found, and which parts of the decision only your prescriber can make.

This is not medical advice. Nothing here tells you what dose to take or whether to switch. Every dosing decision belongs to you and your healthcare provider.

Why is there no Saxenda to Wegovy conversion chart?

A conversion chart between two drugs has to be built on evidence that a dose of one produces a comparable effect to a dose of the other. Manufacturers generate that evidence when a switch is part of the product’s intended use, as with insulins.

Nothing like that exists across GLP-1 molecules. Liraglutide, semaglutide and tirzepatide were each developed and tested on their own escalation schedule, against placebo or against a comparator taken separately. Even the direct comparison trials, like STEP 8, ran the two drugs in parallel groups from the start rather than switching anyone mid-trial [1].

So when you read online that “Saxenda 3 mg is roughly Wegovy 1 mg,” you are reading someone’s estimate, not a regulated statement. It might be a reasonable clinical guess. It is not a label instruction, and this site will not repeat it as one.

What do the weekly labels say about starting dose?

All three of the main weekly options give one starting dose and one escalation schedule, and none of them changes based on what you took before.

Wegovy (semaglutide). The label says the recommended starting dosage of Wegovy injection is 0.25 mg once weekly, and to follow the escalation table to reduce the risk of gastrointestinal side effects. That instruction covers all approved indications. It contains no exception for people switching from another GLP-1 [2].

Ozempic (semaglutide). Ozempic’s label includes switching instructions only between semaglutide products, for example between Rybelsus tablets and Ozempic injection. There is no section describing a switch from a different molecule [3].

Zepbound (tirzepatide). The label states that coadministration with any GLP-1 receptor agonist is not recommended, and that the recommended starting dosage is 2.5 mg injected subcutaneously once weekly for four weeks, increasing in 2.5 mg steps after at least four weeks [4].

The practical meaning is simple. In label terms, someone moving off liraglutide starts the new drug the way a person new to the class starts it. Whether your prescriber follows that exactly, or does something else based on your history and how you tolerated liraglutide, is a clinical judgment they make with you.

Can you take liraglutide and a weekly GLP-1 at the same time?

The labels say not to. Saxenda’s Limitations of Use state that coadministration with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended [5]. Wegovy’s label carries the same limitation for semaglutide-containing products and any other GLP-1 receptor agonist [2]. Zepbound’s label says the same for tirzepatide-containing products and any GLP-1 receptor agonist [4].

This is one of the few genuinely unambiguous statements in this whole topic, and it matters because the “overlap for a week so I don’t lose ground” idea circulates constantly in online groups. Every current label in the class points the other way.

Is there a washout period between the two drugs?

No label gives one.

What the labels do give is pharmacology. Liraglutide’s prescribing information describes a once-daily drug with a half-life measured in hours, not days, which is exactly why it has to be injected every day. Semaglutide and tirzepatide are dosed weekly because they last far longer in the body.

That difference in duration is the reason the switch runs in one direction more easily than the other. Coming off liraglutide, the drug is largely gone within a few days. Coming off a weekly drug, it is not.

Beyond that, the timing is a prescriber decision. Ask yours directly: when do I take my last liraglutide dose, and when do I take the first dose of the new one?

Has anyone actually studied switching off liraglutide?

Once, in a small study, and it is worth knowing its limits.

A prospective study published in Endocrine Practice in 2024 enrolled 151 adults with type 2 diabetes who were on a stable dose of a GLP-1 receptor agonist, including liraglutide 1.2 mg or 1.8 mg, and switched them directly to tirzepatide 5 mg, skipping the usual 2.5 mg starting step. Over 12 weeks, average A1C fell 0.43 percentage points, fasting serum glucose fell 7.83 mg/dL and body weight fell 2.15 kg. Twenty participants, 13.2%, had gastrointestinal events, and three, about 2%, stopped tirzepatide because of adverse events. There were no severe hypoglycemia events and no deaths [6].

Four caveats matter. The study was funded by Eli Lilly, which makes tirzepatide, and several authors were employees. Most participants had been on semaglutide or dulaglutide, not liraglutide, so the liraglutide subgroup was small. Everyone had type 2 diabetes, so it says nothing directly about weight management alone. And the Zepbound and Mounjaro labels still instruct prescribers to start at 2.5 mg, which the study deliberately did not do [4][6].

It is the best available evidence on a direct switch, and it is thin evidence. That is the honest summary.

What happens to my weight during the changeover?

Nobody can promise you an answer, but two trials describe what happened when liraglutide stopped.

The 160-week extension of the SCALE Obesity and Prediabetes trial followed 2,254 adults with prediabetes for three years. Weight loss at week 160 was 6.1% on liraglutide against 1.9% on placebo, a difference of 4.3 percentage points, and half the participants had left the trial before week 160 [7]. In the adolescent SCALE Teens trial, BMI standard deviation score rose more after liraglutide was stopped than after placebo was stopped, an estimated difference of 0.15 [8].

Those numbers describe stopping the drug, not bridging from one drug to another. If your concern is what happens in a gap between prescriptions, that is a direct and reasonable question to put to your prescriber and your pharmacy before the gap happens rather than after.

What if my pharmacy simply cannot get liraglutide?

This has been a real problem, not a theoretical one. The FDA drug shortage database still lists liraglutide injection as currently in shortage, a listing first posted on July 18, 2023, even though several manufacturers reported their presentations as available in entries revised in August and September 2026. Brand Saxenda is listed as limited availability with a note that it will be available until discontinuation in January 2027, and both Victoza package sizes are listed as limited availability because of a shipping delay [9].

The American Diabetes Association’s 2026 Standards of Care address this situation directly. Recommendation 9.31b says that if a glucose-lowering medication is unavailable, for example in a shortage, it is recommended to switch to a different FDA-approved medication with similar efficacy, as clinically appropriate. Recommendation 9.31c says to reassess resuming the original medication once supply returns. Recommendation 9.31a says compounded products that are not FDA-approved are not recommended, because of uncertainty about their content and the resulting concerns about safety, quality and effectiveness [10].

That is a professional body, not a marketer, telling clinicians that a supply-driven switch is legitimate and that compounded substitutes are not the answer.

Does switching mean I will lose more weight?

On the trial averages, a weekly drug does more. STEP 8 randomized 338 adults without diabetes to weekly semaglutide 2.4 mg or daily liraglutide 3.0 mg for 68 weeks. Average weight change was 15.8% with semaglutide and 6.4% with liraglutide, a difference of 9.4 percentage points [1].

But averages are not promises, and STEP 8 also found something people forget: 27.6% of the liraglutide group left the trial against 13.5% of the semaglutide group, while gastrointestinal side effects were reported by similar proportions in both arms, 82.7% and 84.1% [1]. Some of the gap between the two drugs in real life is about who stays on treatment, not only about what the molecule does.

If you are switching because liraglutide was not working well enough for you, the trial data supports the direction. If you are switching because of side effects, the trial data does not promise the new drug will be gentler.

What should I ask my prescriber before switching?

A short list, all of which are questions rather than decisions:

• What starting dose will I be on, and how long will each step last?
• When do I take my last liraglutide dose and my first dose of the new drug?
• Is my insurance going to cover the new drug, and has prior authorization been submitted?
• What is the cash price if coverage is denied, and is staying on generic liraglutide an option if it is?
• What should I do if the new drug is out of stock partway through the escalation?
• If my A1C or blood pressure medicines were adjusted while I was on liraglutide, do they need reviewing?

That last question matters more than people expect. If you have type 2 diabetes and take insulin or a sulfonylurea, the labels for all of these drugs flag hypoglycemia risk when they are combined, and your other doses are your prescriber’s to manage.

Is switching back to liraglutide allowed?

Nothing in the labels prohibits it, and the commonest reason people do it is money. Liraglutide is the only GLP-1 receptor agonist with FDA-approved generics in the United States, which means it is the only one where a pharmacy can dispense a substitute at a generic price. If a weekly brand is denied by an insurer or priced out of reach, generic liraglutide is a real fallback in a way that no generic semaglutide or tirzepatide is, because neither exists.

A restart is not a resumption. You would begin again at the label’s starting dose and work up on the label’s schedule, the same as anyone starting for the first time. Your prescriber decides that.

The short version

There is no conversion chart, no washout instruction, and no labeled dose match between liraglutide and any weekly GLP-1. Every weekly label gives one starting dose that does not depend on what you took before, and every label in the class says not to take two GLP-1 drugs together. One small industry-funded study switched people directly onto tirzepatide 5 mg with reasonable results over 12 weeks, and the label still says to start lower. If a shortage is forcing the change, the ADA’s 2026 guidance explicitly supports switching to another approved drug of similar efficacy and revisiting the original later.

Everything else is a conversation with your prescriber.

Sources

1. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial — JAMA, January 2022
2. WEGOVY (semaglutide) injection and tablets — prescribing information, DailyMed
3. OZEMPIC (semaglutide) — prescribing information, DailyMed
4. ZEPBOUND (tirzepatide) injection — prescribing information, DailyMed
5. SAXENDA (liraglutide) injection, solution — prescribing information, DailyMed, revised 02/2026
6. Jabbour S et al. Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment. Endocrine Practice, 2024
7. le Roux CW et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes. Lancet, 2017
8. Kelly AS et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. New England Journal of Medicine, 2020
9. FDA Drug Shortages — Liraglutide Injection, current shortage record, retrieved 2026-09-14
10. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care 49(Suppl 1):S183–S215
11. VICTOZA (liraglutide) injection — prescribing information, DailyMed